Fig. 4
From: Myometrial oxidative stress drives MED12 mutations in leiomyoma
CRISPR/Cas 9-mediated targeted replacement of c.130G with 8-oxodG and misrepair analysis in myometrial cells. a A diagram illustrates the targeted replacement of c.130G with modified guanine (8-oxodG) on the ssDNA donor by CRISPR/Cas9, followed by deep sequencing analysis of misrepair caused by 8-oxodG. c.138T>C was used as an index. b Dot plot revealed the misrepair reads (c.130G>T, C, A: 34.3%) in the myometrial myo-hTERT cell line detected by lower depth (15k reads/sample) deep sequencing analysis after CRISPR/Cas9 editing to c.1308-oxodG (red dots) and without 130G editing control (blue dots). c Dot plot illustrated c.130G>T, A, C misrepair (44.2, 52.1, 21.7 and 18.2%, respectively) in the 4 myometrial samples with CRISPR/Cas9 editing to c.1308-oxodG in MED12 exon2 with the c.138T index in high depth deep sequencing analysis (500k reads/sample).  d. Pie graphs showed the percentage of different mutation types in myo-hTERT cells and three cases of primary myometrial cells with CRISPR/Cas9 editing. e Histobars showed the percentage of c.130G>T, A, C misrepair in four myometrial samples (n=4).